Assessment of Serum Interleukin-6 (IL -6) Levels and Its Role in Severity of Psoriasis A Hospital Based Case Control Study in M.Y. Hospital, Indore M.P.
Authors/Creators
- 1. Demonstrator, Department of Biochemistry, C.I.M.S. Chhindwara MP
- 2. Senior Resident, Department of Anatomy, L.N. Medical College Bhopal MP
- 3. Associate Professor, department of Psychiatry, C.I.M.S. Chhindwara MP
- 4. Assistant Professor, Department of Biochemistry, MGM Medical College Indore MP
Description
Introduction: Psoriasis is a chronic immuno-inflammatory proliferative skin disease. It is characterized by excessive proliferation of epidermal cells, impaired function of epidermal barrier at the sites of skin lesions and infiltration of skin by activated inflammatory cells. Interleukin 6 (IL-6), a major mediator of the host response to tissue injury and infection, is produced by both epidermal cells and leukocytes in culture. Since immune and inflammatory factors play an important role in the pathogenesis of psoriasis, we aimed to assess the relationship between the serum levels of IL-6 and pathogenesis and severity of psoriasis. Material and Methods: This cross sectional study included 50 Confirmed & diagnosed cases of psoriasis patients (case group) and 50 age and gender matched healthy subjects (control group). Serum IL-6 levels were measured for both the groups. Results: In our study the mean serum IL-6 in case group was higher 6.97 ± 5.43 pg/ml than in control group it was 2.22 ± 2.10 pg/ml thus, serum IL-6 level might be useful for evaluating the disease activity of psoriasis as Novel biomarker. Conclusion: As Interleukin-6 (IL-6) is an important sensitive, diagnostic and prognostic marker in many systemic inflammatory diseases, its detection and serial measurements helps to provide a novel link to evaluate the disease activity, severity and response to treatment in psoriasis.
Abstract (English)
Introduction: Psoriasis is a chronic immuno-inflammatory proliferative skin disease. It is characterized by excessive proliferation of epidermal cells, impaired function of epidermal barrier at the sites of skin lesions and infiltration of skin by activated inflammatory cells. Interleukin 6 (IL-6), a major mediator of the host response to tissue injury and infection, is produced by both epidermal cells and leukocytes in culture. Since immune and inflammatory factors play an important role in the pathogenesis of psoriasis, we aimed to assess the relationship between the serum levels of IL-6 and pathogenesis and severity of psoriasis. Material and Methods: This cross sectional study included 50 Confirmed & diagnosed cases of psoriasis patients (case group) and 50 age and gender matched healthy subjects (control group). Serum IL-6 levels were measured for both the groups. Results: In our study the mean serum IL-6 in case group was higher 6.97 ± 5.43 pg/ml than in control group it was 2.22 ± 2.10 pg/ml thus, serum IL-6 level might be useful for evaluating the disease activity of psoriasis as Novel biomarker. Conclusion: As Interleukin-6 (IL-6) is an important sensitive, diagnostic and prognostic marker in many systemic inflammatory diseases, its detection and serial measurements helps to provide a novel link to evaluate the disease activity, severity and response to treatment in psoriasis.
Files
IJTPR,Vol13,Issue7,Article1 (1).pdf
Files
(350.6 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:506027783b015e447f548961495a9cd7
|
350.6 kB | Preview Download |
Additional details
Dates
- Accepted
-
2023-05-26
Software
References
- 1. Napolitano M, Caso F, Scarpa R, Megna M, Patrì A, Balato N, Costa L. Psoriatic arthritis and psoriasis: differential diagnosis. Clin Rheumatol. 2016;35(8):1893–901. 2. Gerdes S, Osadtschy S, Rostami-Yazdi M, et al. Leptin, adiponectin, visfatin and retinolbinding protein-4–mediators of comorbidities in patients with psoriasis? Exp Dermatol 2012; 21: 43-7. 3. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004; 89: 2548-56. 4. Fujishima S, Watanabe H, Kawaguchi M, et al. Involvement of IL-17F via the induction of IL6 in psoriasis. Arch Dermatol Res 2010; 302: 499-505. 5. Pietrzak AT, Zalewska A, Chodorowska G, et al. Cytokines and anticytokines in psoriasis. Clin Chim Acta 2008; 394: 7-21. 6. Fry L. Psoriasis. Br J Dermatol. 1988; 119(4):445–461. 7. Lever WF, Schaumburg-Lever G. Histopathology of the Skin. Philadelphia, Pa: JB Lippincott; 1975:135– 146. 8. Liang, Y.; Sarkar, M.K.; Tsoi, L.C.; Gudjonsson, J.E. Psoriasis: A mixed autoimmune and autoinflammatory disease. Curr. Opin. Immunol. 2017; 49: 1–8. 9. Bonifati C, Ameglio F. Cytokines in psoriasis. Int J Dermatol. 1999;38(4):241–251. 10. Arican O, Aral M, Sasmaz S, et al. Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17 and IL-18 in patients with active psoriasis and correlation with disease severity. Mediators Inflamm 2005; 5: 273-9. 11. Neuner P, Urbanski A, Trautinger F, et al. Increased IL-6 production by monocytes and keratinocytes in patients with psoriasis. J Invest Dermatol 1991; 97: 27-33. 12. Balato A, Schiattarella M, Di Caprio R, et al. Effects of adalimumab therapy in adult subjects with moderate-to-severe psoriasis on Th17 pathway. J Eur Acad Dermatol Venereol 2014; 28: 1016-24. 13. Abanmi A, Al Harthi F, Al Agla R, Khan HA, Tariq M. Serum levels of proinflammatory cytokines in psoriasis patients from Saudi Arabia. Int J Dermatol. 2005;44(1):82–83 14. Mizutani H, Ohmoto Y, Mizutani T, Murata M, Shimizu M. Role of increased production of monocytes TNF-α, IL-1β and IL-6 in psoriasis: relation to focal infection, disease activity and responses to treatments. J Dermatol Sci. 1997;14(2):145–153 15. Ozer Arican,1 Murat Aral,2 Sezai Sasmaz,1 and Pinar Ciragil2 Serum Levels of TNF-α, IFN-γ, IL-6, IL-8, IL-12, IL-17, and IL-18 in Patients with Active Psoriasis and Correlation With Disease Severity, Mediators of Inflammation. 2005:5: 273–279 PII: 16. Szepietowski JC, Bielicka E, Nockowski P, Noworolska A, Wasik F. Increased interleukin7 levels in the sera of psoriatic patients: lack of correlations with interleukin-6 levels and disease intensity. Clin Exp Dermatol. 2000; 25(8):643–647.